Your browser is no longer supported. Please, upgrade your browser.
Settings
BIIB Biogen Inc. daily Stock Chart
BIIB [NASD]
Biogen Inc.
IndexS&P 500 P/E20.41 EPS (ttm)14.78 Insider Own0.10% Shs Outstand235.17M Perf Week-0.94%
Market Cap70.93B Forward P/E16.97 EPS next Y17.78 Insider Trans-16.22% Shs Float234.94M Perf Month-10.07%
Income3.49B PEG1.30 EPS next Q3.92 Inst Own91.50% Short Float1.14% Perf Quarter-22.23%
Sales10.30B P/S6.89 EPS this Y58.40% Inst Trans-0.95% Short Ratio1.14 Perf Half Y-27.78%
Book/sh53.44 P/B5.64 EPS next Y11.64% ROA23.30% Target Price389.27 Perf Year-9.92%
Cash/sh10.07 P/C29.95 EPS next 5Y15.74% ROE30.70% 52W Range265.00 - 480.18 Perf YTD-11.14%
Dividend- P/FCF21.96 EPS past 5Y29.90% ROI26.20% 52W High-37.18% Beta0.91
Dividend %- Quick Ratio1.90 Sales past 5Y17.30% Gross Margin88.40% 52W Low13.82% ATR11.36
Employees7550 Current Ratio2.20 Sales Q/Q7.00% Oper. Margin44.80% RSI (14)42.22 Volatility3.05% 3.73%
OptionableYes Debt/Eq0.05 EPS Q/Q30.60% Profit Margin33.90% Rel Volume0.76 Prev Close304.21
ShortableYes LT Debt/Eq0.05 EarningsJul 24 BMO Payout0.00% Avg Volume2.35M Price301.63
Recom2.10 SMA20-1.25% SMA50-13.38% SMA200-19.50% Volume1,774,400 Change-0.85%
Sep-01-15Initiated Raymond James Strong Buy $400
Aug-11-15Initiated H.C. Wainwright Buy $380
Jul-27-15Upgrade Bernstein Mkt Perform → Outperform $436 → $385
Jul-27-15Reiterated RBC Capital Mkts Outperform $525 → $450
Jul-27-15Reiterated Argus Buy $450 → $360
Jul-27-15Downgrade Robert W. Baird Outperform → Neutral $480 → $316
Jul-24-15Downgrade BMO Capital Markets Outperform → Market Perform $511 → $360
Jul-22-15Downgrade Piper Jaffray Overweight → Neutral
Jul-14-15Upgrade BofA/Merrill Neutral → Buy
Jun-11-15Reiterated Leerink Partners Outperform $532 → $512
Jun-09-15Initiated Guggenheim Neutral
Apr-27-15Reiterated UBS Neutral $350 → $422
Apr-27-15Reiterated Argus Buy $440 → $450
Mar-23-15Downgrade Stifel Buy → Hold
Feb-02-15Reiterated Argus Buy $385 → $440
Jan-30-15Reiterated RBC Capital Mkts Outperform $400 → $445
Jan-30-15Reiterated Deutsche Bank Buy $430 → $460
Oct-22-14Upgrade Robert W. Baird Neutral → Outperform $374 → $382
Aug-19-14Resumed Stifel Buy $376
Jul-29-14Reiterated Argus Buy $360 → $385
Sep-03-15 07:18PM  SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses in Excess of $100,000 Investing in Biogen Inc. to Contact the Firm Marketwired
06:25PM  Kyle Bass is slamming the group blocking his new, big short strategy
02:15PM  After Biogen deal, Florida biotech opening Cambridge office at bizjournals.com
12:41PM  3 Biotech Stocks to Buy in the Middle of a Turbulent Market at Motley Fool
08:30AM  Neurocrine Biosciences Announces the Appointment of Dr. Alfred W. Sandrock to its Board of Directors PR Newswire
Sep-02-15 02:26PM  Biogen Wins Round In Patent Fight Vs. Kyle Bass at Investor's Business Daily
01:15PM  Chip, Biotech ETFs, Gutted In August, Lead Relief Rally at Investor's Business Daily
11:24AM  Biogen patent survives challenge by hedge fund manager Kyle Bass
10:38AM  Amgen, Novartis Alzheimer's Deal Gets Cautious Praise at Investor's Business Daily
Sep-01-15 04:24PM  Biogen: 'A Nice Little Trade' Or Heading To New Lows?
04:04PM  Jim Cramer -- A Fed Rate Hike Won't Stop Profit Opportunities at TheStreet
01:05PM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Biogen Inc. of Pendency of Class Action Lawsuit and a Lead Plaintiff Deadline of October 19, 2015 -- BIIB GlobeNewswire
12:41PM  Gilead Sciences: Most Enticing at Barrons.com
11:05AM  A Hidden Biotech Marvel
06:15AM  Coverage initiated on Biogen by Raymond James
06:01AM  BIOGEN INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation
Aug-31-15 04:20PM  Applied Genetic Meets Enrolment Milestone in XLRS Study
03:49PM  ALERT: Rosen Law Firm Reminds Biogen Inc. Investors of Important Deadline in Class Action Business Wire
Aug-30-15 07:36AM  We Believe Healthcare's Next Biotech Buyout Target Is at Motley Fool
Aug-28-15 03:34PM  Gilead & Amgen Account for Nearly 75% of the Biotech Profit Pool at Barrons.com
Aug-27-15 11:06AM  Biogen And Gilead Sciences Catch The Eye Of Short Sellers
11:02AM  'We See Opportunity in Biogen, Gilead and Regeneron,' Morgan Stanley Says at Barrons.com
Aug-26-15 03:15PM  Here's who Mass. biotechs are supporting in recent elections (BBJ DataCenter) at bizjournals.com +5.86%
12:35PM  Biogen Inc. Shareholder Alert: Former SEC Attorney Willie Briscoe and Powers Taylor Investigate Possible Breaches of Fiduciary Duty by Officers and Directors Business Wire
08:55AM  Short Sellers Become More Focused in Major Biotechs at 24/7 Wall St.
08:55AM  Biotech Stock Roundup: Acorda Gains on Patent Issues, Vital Crushed by Liver Data
Aug-25-15 11:25AM  AMAG is a Hidden Biotech Gem That is Exploding
11:09AM  Acorda Stock Jumps After Bass Patent Petitions Nixed at Investor's Business Daily
08:51AM  Biogen (BIIB) Crumbles: Stock Falls by 5.9%
Aug-24-15 05:00PM  Trading the historic market dip: 6 stocks to buy -5.85%
01:53PM  Biogen Pipeline Doesn't Justify High Valuation at Barrons.com
06:53AM  Biotech blues despite 12% gain YTD
Aug-21-15 04:13PM  How Big Biotech Spents It's Money at Barrons.com
01:15PM  Why Medivation is a Stunning Biotech Opportunity
12:59PM  Three Bay State biotechs that bucked the recent sell-off and why at bizjournals.com
10:43AM  4 Reasons To Keep An Eye On Biotech Stock Celgene
Aug-20-15 02:04PM  Using ETFs To Run Your Own Hedge Fund
01:03PM  Key Financial Ratios to Analyze Biotech Companies at Investopedia
10:25AM  Applied Genetic Solidifies Deal With Biogen
09:42AM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Biogen Inc. of Pendency of Class Action Lawsuit and a Lead Plaintiff Deadline of October 19, 2015 -- BIIB Marketwired
Aug-19-15 06:29PM  Celgene May be The Single Best Biotech in the World
05:14PM  Top trades: Target, SunEdison, Biogen & more
04:05PM  AGTC Announces Strategic Collaboration With Biogen Effective and Biogen Equity Investment Closed GlobeNewswire
08:33AM  Biotech Stock Roundup: Kite Addresses Patient Death Concerns, Omeros Soars on Data
Aug-18-15 06:35PM  EQUITY ALERT: The Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Biogen Inc. to Recover Investor Losses Business Wire
04:49PM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Biogen Inc. of Pendency of Class Action Lawsuit and a Lead Plaintiff Deadline of October 19, 2015 -- BIIB GlobeNewswire
01:40PM  Biogen partners with Columbia to find genetic 'signposts' of ALS at bizjournals.com
01:23PM  Five Reasons to Buy Biogen at Barrons.com
07:00AM  Biogen, the ALS Association and Columbia University Medical Center Collaborate to Drive Understanding of Genetic Influence in ALS Business Wire
Aug-17-15 01:40PM  Opposing viewpoints on the existence (or not) of a 'bubble' in biotech at bizjournals.com
11:51AM  Who Should Allergan Buy? at Barrons.com
07:00AM  Results from B-YOND Extension Study Reinforce Long-Term Clinical Profile of ALPROLIX for the Treatment of Hemophilia B Business Wire
Aug-15-15 08:06AM  3 Reasons Why I Just Bought Biogen Inc. Stock at Motley Fool
01:39AM  [$$] Less Correlation Good News for Investors at Barrons.com
Aug-14-15 01:35PM  Biotech still great growth sector: Pro
01:34PM  Top 3 Biotech ETFs at Investopedia
Aug-13-15 12:08PM  AstraZeneca Plc Earnings Q2*, 2015
Aug-12-15 08:55AM  Short Sellers Run for Cover From Major Biotechs at 24/7 Wall St.
07:35AM  5 Top BioPharma Stocks That May Have Sold Off Too Much and Become Bargains at 24/7 Wall St.
Aug-11-15 07:23PM  Lightning Round: It's become too hard to play at CNBC
12:45PM  A misguided attempt to rein in drug costs in Massachusetts at bizjournals.com
08:45AM  Top Analyst Upgrades and Downgrades: Adobe, Biogen, Google, PDC Energy, Rackspace, XL Group and Many More at 24/7 Wall St.
Aug-10-15 05:11PM  Today's Stocks to Watch Roundup: Buffett, Biotech, and a Commodity Boon at Barrons.com
02:08PM  IBB claws its way back
01:31PM  Biotech: Is This the End of the Rally? at Barrons.com
12:24PM  Don't Give up on Biogen: Deutsche Bank Sees Fair Value at $400 at Barrons.com
11:21AM  Cramer -- Biogen Rally Could Boost Sector, Freeport-McMoRan Hopes for Rebound at TheStreet
09:54AM  Cramer's Stop Trading: Biogen
08:20AM  3 Large Biotech Stocks to Buy Despite Higher Interest Rates Coming at 24/7 Wall St.
07:04AM  Extension study data supporting long-term safety and efficacy of Eloctate┬«/Elocta┬« published in Haemophilia GlobeNewswire
07:00AM  Extension Study Data Supporting Long-Term Safety and Efficacy of Eloctate┬« Published in Haemophilia Business Wire
Aug-09-15 11:16AM  Don't fear media selloff -buy into it: Trader at CNBC
Aug-07-15 06:21PM  Risk Averse? Big Cap 20 Stocks Offer Safety, Growth Potential
02:39PM  The Historical Correlation Between Biotech Stocks And Interest Rates
08:55AM  ETF Analysis: iShares NASDAQ Biotechnology at Investopedia
Aug-06-15 06:14PM  Vanguard Health Care Fund Buys 2 New Stakes in Second Quarter -5.61%
05:16PM  Biogen Drops on Doctor Worry Over Drug Class Including Tecfidera at Bloomberg
12:40PM  These Two Biotechs Boast Big EPS Growth Rates at Investor's Business Daily
09:21AM  3 Crashing Healthcare Stocks That You Can Buy at Motley Fool
08:33AM  Amgen, Inc. Earnings Analysis: By the Numbers Q2*, 2015
Aug-05-15 05:37PM  CVS strips Viagra, other top drugs, from insurance coverage
03:02PM  Here's Why Biogen Lost $20 Billion in Market Value in July at Motley Fool
02:59PM  3 Hot Stocks to Trade (or Not) -- Must-See Charts at TheStreet
12:47PM  Mid-Cap Biotech Stocks Outperform in Week Ended July 24
12:47PM  Benchmark Indexes Outperform Biotech ETFs in Week Ended July 24
Aug-04-15 06:12PM  Cramer: Why Apple is not for the squeamish at CNBC
03:44PM  Will Biogen Win From Novartis MS Drug Safety Label Change?
02:30PM  Heres what a combined Shire-Baxalta would look like for the Bay State at bizjournals.com
02:14PM  Regeneron Tops 3 Med Stocks Moving Big On Earnings
01:00PM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation of Biogen Inc. and Its Board of Directors in Connection with Possible Violations of Federal Securities Laws -- BIIB PR Newswire
11:10AM  Why we're 'losing' Apple: Technician at CNBC
08:35AM  3 Potential Huge Takeover Targets in Biotech at 24/7 Wall St.
Aug-03-15 03:45PM  Analyst outlines two possible futures for Biogen: One good, one bad (Video) at bizjournals.com
01:05PM  Biogen Stock Fell for the Week Ending July 24
12:55PM  AbbVie, Inc. Earnings Q2*, 2015
12:27PM  BIIB INVESTORS: The Law Offices of Howard G. Smith Announces An Investigation On Behalf Of Biogen, Inc. Investors Business Wire
09:05AM  Biogen Lowers Its Full-Year 2015 Outlook in 2Q15
08:48AM  Biogen, Inc. Earnings Analysis: By the Numbers Q2*, 2015
Aug-02-15 09:12AM  This Latest Study Adds 1 More Piece to the Alzheimer's Puzzle at Motley Fool
Aug-01-15 09:05AM  Tech and Biotech See Big-Time Insider Buying This Week Apple, Biogen, Qualcomm and More at 24/7 Wall St.
Biogen Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurological, autoimmune, and hematologic disorders in the United States and internationally. It provides AVONEX to treat relapsing multiple sclerosis (MS); TYSABRI to treat relapsing forms of MS and Crohn's disease; PLEGRIDY to treat relapsing MS; TECFIDERA to treat MS; FAMPYRA to improve walking in adult patients with MS; ALPROLIX to treat hemophilia B; ELOCTATE to treat hemophilia A; RITUXAN for treating non-Hodgkin's lymphoma, rheumatoid arthritis, and chronic lymphocytic leukemia (CLL), as well as two forms of ANCA-associated vasculitis; GAZYVA for the treatment of patients with previously untreated CLL; and FUMADERM to treat severe plaque psoriasis in adult patients. The company's products that completed Phase III clinical trials comprise ZINBRYTA, a monoclonal antibody in relapsing MS. Its products under Phase III clinical trials consist of TYSABRI for secondary progressive MS and spinal muscular atrophy; ISIS SMN for spinal muscular atrophy; and GAZYVA for non-Hodgkin's lymphoma. The company's Phase II clinical trial products include Anti-LINGO for optic neuritis and MS; Neublastin for neuropathic pain; TYSABRI for optic neuritis; ANTI-TWAEK for lupus nephritis; BAN2401 and E2609 for Alzheimer's disease; and GAZYVA for lupus nephritis, as well as Phase IIa clinical trial products include STX-100 for idiopathic pulmonary fibrosis. Its Phase I clinical trial products comprise BIIB037 for Alzheimer's disease; ISIS DMPK for myotonic dystrophy; BIIB061 for MS; and Anti-BDCA2 for systemic lupus erythematosus, as well as Phase Ib clinical trial products include BIIB037 for Alzheimer's disease and Anti-C for systemic lupus erythematosus. The company was formerly known as Biogen Inc. and changed its name to Biogen Inc. in March 2015. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
PAPADOPOULOS STELIOSDirectorJul 27Buy304.8810,0003,048,7755,000Jul 27 05:03 PM
Posner Brian SDirectorJun 22Sale415.00470195,0505,275Jun 23 04:14 PM
WILLIAMS DOUGLAS EEVP Research & DevelopmentJun 19Sale410.003,8411,574,81011,817Jun 22 04:15 PM
Posner Brian SDirectorJun 15Sale386.64400154,6565,745Jun 16 06:54 PM
Koppel AdamSVP, Chief Strategy OfficerJun 02Option Exercise0.002,38402,514Jun 04 05:49 PM
SCANGOS GEORGE AChief Executive OfficerJun 01Sale398.871,362543,26141,090Jun 02 04:10 PM
COVINO GREGORY FVP, Chief Accounting OfficerMay 01Option Exercise386.22347134,0181,874May 05 04:36 PM
SCANGOS GEORGE AChief Executive OfficerMay 01Sale377.521,362514,18242,452May 05 04:34 PM
Artavanis-Tsakonas SpyridonSVP, Chief Scientific OfficerApr 02Option Exercise0.0097502,134Apr 03 04:24 PM
SCANGOS GEORGE AChief Executive OfficerApr 01Sale423.201,362576,39843,814Apr 02 04:29 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerMar 27Sale430.12430184,9528,574Mar 30 04:13 PM
Cox JohnEVP Pharmaceutical Oper & TechMar 25Option Exercise65.855,066333,57137,577Mar 26 04:31 PM
Cox JohnEVP Pharmaceutical Oper & TechMar 25Sale449.0612,0105,393,21125,567Mar 26 04:31 PM
Rowinsky Eric KDirectorMar 20Option Exercise59.8211,667697,92022,977Mar 23 04:33 PM
Rowinsky Eric KDirectorMar 20Sale475.0011,6675,541,82511,310Mar 23 04:33 PM
Rowinsky Eric KDirectorMar 19Option Exercise59.822,333139,56013,643Mar 20 05:03 PM
Rowinsky Eric KDirectorMar 19Sale436.142,3331,017,50811,310Mar 20 05:03 PM
Rowinsky Eric KDirectorMar 17Option Exercise59.824,667279,18015,977Mar 18 05:03 PM
Rowinsky Eric KDirectorMar 17Sale425.454,6671,985,58911,310Mar 18 05:03 PM
DiPietro KennethEVP Human ResourcesMar 16Sale415.46803333,6140Mar 17 08:10 PM
SCANGOS GEORGE AChief Executive OfficerMar 13Sale412.69537221,61345,176Mar 16 08:39 PM
PANGIA ROBERT WDirectorMar 10Option Exercise47.713,625172,95417,998Mar 11 04:13 PM
SHERWIN STEPHEN ADirectorMar 10Option Exercise59.826,000358,92010,150Mar 11 04:17 PM
SHERWIN STEPHEN ADirectorMar 10Sale409.676,0002,458,0204,150Mar 11 04:17 PM
PANGIA ROBERT WDirectorMar 10Sale413.403,6251,498,57814,873Mar 11 04:13 PM
Rowinsky Eric KDirectorMar 09Option Exercise59.824,666279,12015,976Mar 11 04:15 PM
Rowinsky Eric KDirectorMar 09Sale417.234,6661,946,79511,310Mar 11 04:15 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerMar 02Sale409.493,1741,299,7159,004Mar 03 04:44 PM
SCANGOS GEORGE AChief Executive OfficerMar 02Sale410.67825338,80345,713Mar 03 04:39 PM
SCANGOS GEORGE AChief Executive OfficerFeb 19Sale401.04537215,35846,538Feb 20 04:28 PM
SCANGOS GEORGE AChief Executive OfficerFeb 17Sale389.11825321,01647,075Feb 18 04:45 PM
Holtzman Steven HEVP Corporate DevelopmentFeb 17Sale389.112,128828,0264,321Feb 18 04:41 PM
DiPietro KennethEVP Human ResourcesFeb 17Sale389.111,188462,263803Feb 18 04:37 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerFeb 17Sale389.11418162,64815,004Feb 18 04:36 PM
SCANGOS GEORGE AChief Executive OfficerFeb 12Option Exercise0.0015,599045,547Feb 17 09:32 PM
COVINO GREGORY FVP, Chief Accounting OfficerFeb 12Option Exercise0.0047101,450Feb 17 09:16 PM
Holtzman Steven HEVP Corporate DevelopmentFeb 12Option Exercise0.003,63407,152Feb 17 08:54 PM
Artavanis-Tsakonas SpyridonSVP, Chief Scientific OfficerFeb 12Option Exercise0.001,20101,318Feb 17 08:50 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerFeb 12Option Exercise0.001,605015,805Feb 17 08:47 PM
Clancy Paul JExecutive VP and CFOFeb 12Option Exercise0.004,299022,960Feb 17 08:44 PM
Cox JohnEVP Pharmaceutical Oper & TechFeb 12Option Exercise0.003,738033,214Feb 17 08:40 PM
WILLIAMS DOUGLAS EEVP Research & DevelopmentFeb 12Option Exercise0.005,200016,481Feb 17 08:37 PM
ALEXANDER SUSAN HEVP, Chief Legal OfficerFeb 12Option Exercise0.003,769028,634Feb 17 08:34 PM
DiPietro KennethEVP Human ResourcesFeb 12Option Exercise0.003,76402,706Feb 17 08:30 PM
Kingsley Stuart AEVP, Global Comm. OperationsFeb 12Option Exercise0.003,60108,771Feb 17 08:26 PM
SCANGOS GEORGE AChief Executive OfficerFeb 10Option Exercise0.0018,833043,148Feb 11 04:25 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerFeb 10Sale398.111,143455,03914,574Feb 11 04:26 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerFeb 09Option Exercise0.001,824016,398Feb 10 05:11 PM
Kingsley Stuart AEVP, Global Comm. OperationsFeb 09Option Exercise0.001,82407,088Feb 10 05:08 PM
Cox JohnEVP Pharmaceutical Oper & TechFeb 09Option Exercise0.004,691032,744Feb 10 05:07 PM
Clancy Paul JExecutive VP and CFOFeb 09Option Exercise0.004,691022,194Feb 10 05:06 PM
SCANGOS GEORGE AChief Executive OfficerFeb 09Option Exercise0.0011,270029,255Feb 11 04:25 PM
ALEXANDER SUSAN HEVP, Chief Legal OfficerFeb 09Option Exercise0.003,909027,716Feb 10 05:12 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerFeb 09Sale398.05856340,73114,574Feb 10 05:11 PM
WILLIAMS DOUGLAS EEVP Research & DevelopmentFeb 08Option Exercise0.003,468014,542Feb 10 05:14 PM
ALEXANDER SUSAN HEVP, Chief Legal OfficerFeb 08Option Exercise0.002,498024,625Feb 10 05:12 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerFeb 08Option Exercise0.001,277015,851Feb 10 05:11 PM
Holtzman Steven HEVP Corporate DevelopmentFeb 08Option Exercise0.002,70505,802Feb 10 05:10 PM
Kingsley Stuart AEVP, Global Comm. OperationsFeb 08Option Exercise0.002,63606,147Feb 10 05:08 PM
Cox JohnEVP Pharmaceutical Oper & TechFeb 08Option Exercise0.004,023029,590Feb 10 05:07 PM
Clancy Paul JExecutive VP and CFOFeb 08Option Exercise0.003,191018,646Feb 10 05:06 PM
DiPietro KennethEVP Human ResourcesFeb 02Sale389.031,656644,2340Feb 03 06:35 PM
DiPietro KennethEVP Human ResourcesFeb 01Option Exercise0.002,46302,463Feb 02 07:46 PM
WILLIAMS DOUGLAS EEVP Research & DevelopmentFeb 01Option Exercise0.005,157013,133Feb 02 07:43 PM
Holtzman Steven HEVP Corporate DevelopmentFeb 01Option Exercise0.005,15705,157Feb 02 07:40 PM
Artavanis-Tsakonas SpyridonSVP, Chief Scientific OfficerDec 15Sale346.501,981686,417352Dec 16 04:36 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerDec 04Sale345.88440152,18714,574Dec 05 05:20 PM
Holtzman Steven HEVP Corporate DevelopmentDec 02Sale335.651,749587,0520Dec 03 04:32 PM
Holtzman Steven HEVP Corporate DevelopmentNov 11Sale330.001,750577,5001,749Nov 12 04:24 PM
SCANGOS GEORGE AChief Executive OfficerNov 03Sale320.781,128361,84017,985Nov 04 04:18 PM
SCANGOS GEORGE AChief Executive OfficerOct 01Sale330.971,127373,00319,113Oct 02 04:44 PM
Holtzman Steven HEVP Corporate DevelopmentOct 01Sale330.971,750579,1983,499Oct 02 04:42 PM